NCT03829254
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
At risk: Primary completion moved at least 10 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Aug 2026 to Jul 2027
- Eligibility criteria expanded, about 42 words
- Secondary endpoints: details revised at 12 of 21 entries
- Notable Eligibility criteria shortened, about 61 words
- Site details revised at 4 of 9 sites
- Notable Eligibility criteria expanded, about 60 words
- Study sites: 5 to 9
- Notable Primary and study completion dates: Jun 2024 to Aug 2026
- Eligibility criteria expanded, about 54 words
- Enrollment target: 94 to 135
- Minor Primary and study completion dates: Jan 2024 to Jun 2024v10
Show 8 earlier versionsHide 8 earlier versions
- Minor Primary and study completion dates: Sep 2023 to Jan 2024v9
- Notable Eligibility criteria expanded, about 114 words
- Secondary endpoints: 10 to 21
- Minor Study sites: 3 to 5v7
Notable Primary and study completion dates: Jul 2022 to Sep 2023v6 Show 4 more changesShow less
- Eligibility criteria expanded, about 250 words
- Interventions: NUC-7738 (Drug) to NUC-7738 (Drug), Pembrolizumab (Drug)
- Secondary endpoints: details revised at 4 of 10 entries
- Study arms: 1 to 2
Notable Phase: Phase 1 to Phase 1/2v5 Show 5 more changesShow less
- Eligibility criteria expanded, about 47 words
- Primary endpoints: 5 to 11
- Secondary endpoints: 7 to 10
- Site contacts updated at 2 of 3 sites
- Study title expanded, about 4 words
- Notable Enrollment target: 61 to 94
- Primary and study completion dates: Nov 2021 to Jul 2022
- Eligibility criteria shortened, about 8 words
- Notable Primary and study completion dates pushed to Nov 2021
- Eligibility criteria expanded, about 7 words
- Study description shortened, about 416 words
- Site contacts updated at 3 of 3 sites
- Notable Start date changed from estimate of Feb 2019 to Jun 17, 2019v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (21)
Show 16 moreShow less
Arms and interventions
NUC-7738 administered by intravenous infusion on a weekly or fortnightly schedule. In the weekly dosing schedule, NUC-7738 is administered on Days 1 and 8 of a 14-day cycle. In the fortnightly dosing schedule, NUC-7738 is administered on Day 1 of a 14-day cycle.
NUC-7738 administered by intravenous infusion on a weekly schedule on Days 1, 8 and 15 of a 21-day cycle. Pembrolizumab administered by intravenous infusion every 3 weeks on Day 1 of a 21-day cycle.
Drugs: NUC-7738, Pembrolizumab
Sites
9 sites in 1 country